Colestilan - Mitsubishi Tanabe Pharma
Alternative Names: BindRen; Cholebine; Colestimide; MCI-196Latest Information Update: 02 Jul 2019
Price :
$50 *
At a glance
- Originator Mitsubishi Chemical; Mitsubishi Pharma Corporation
- Developer Mitsubishi Chemical; Mitsubishi Tanabe Pharma Corporation
- Class Antihyperlipidaemics; Imidazolines; Polymers; Small molecules
- Mechanism of Action Bile acid binding protein modulators; Phosphate binding protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hypercholesterolaemia; Hyperphosphataemia
- Discontinued Type 2 diabetes mellitus
Most Recent Events
- 08 May 2019 Launched for Hyperphosphataemia in Poland prior May 2019 (PO)
- 08 May 2015 Discontinued - Phase-I for Hyperphosphataemia in Japan (PO) (Mitsubishi Tanabe Pharma pipeline, May 2015)
- 08 May 2015 Discontinued - Phase-II for Type-2 diabetes mellitus in Japan (PO) (Mitsubishi Tanabe Pharma pipeline, May 2015)